2. Academic Validation
  3. Advanced Glycation End Products, Diabetes, and Bone Strength

Advanced Glycation End Products, Diabetes, and Bone Strength

  • Curr Osteoporos Rep. 2016 Dec;14(6):320-326. doi: 10.1007/s11914-016-0332-1.
Masahiro Yamamoto 1,  Toshitsugu Sugimoto 2
Affiliations

Affiliations

  • 1 Internal Medicine 1, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan. masa-ya@med.shimane-u.ac.jp.
  • 2 Internal Medicine 1, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.
PMID: 27704396 DOI: 10.1007/s11914-016-0332-1
Abstract

Diabetic patients have a higher fracture risk than expected by their bone mineral density (BMD). Poor bone quality is the most suitable and explainable cause for the elevated fracture risk in this population. Advanced glycation end products (AGEs), which are diverse compounds generated via a non-enzymatic reaction between reducing sugars and amine residues, physically affect the properties of the bone material, one of a component of bone quality, through their accumulation in the bone collagen fibers. On the Other hand, these compounds biologically act as agonists for these receptors for AGEs (RAGE) and suppress bone metabolism. The concentrations of AGEs and endogenous secretory RAGE, which acts as a "decoy receptor" that inhibits the AGEs-RAGE signaling axis, are associated with fracture risk in a BMD-independent manner. AGEs are closely associated with the pathogenesis of this unique clinical manifestation through physical and biological mechanisms in patients with diabetes mellitus.

Keywords

Bone quality; Crosslink; Fracture; Material properties; Pentosidine; Receptor for advanced glycation end products (RAGE).

Figures